Cargando…

Influence of intensive lipid‐lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study

INTRODUCTION: Coronary CT angiography (CTA) derived fractional flow reserve (FFR(CT)) shows high diagnostic performance when compared to invasively measured FFR. Presence and extent of low attenuation plaque density have been shown to be associated with abnormal physiology by measured FFR. Moreover,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mortensen, Martin B., Sand, Niels‐Peter, Busk, Martin, Jensen, Jesper M., Grove, Erik L., Dey, Damini, Iraqi, Nadia, Updegrove, Adam, Fonte, Tim, Mathiassen, Ole N., Hosbond, Susanne, Bøtker, Hans E., Leipsic, Jonathon, Narula, Jagat, Nørgaard, Bjarne L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Clinical Study Design
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574753/ https://www.ncbi.nlm.nih.gov/pubmed/36056636 http://dx.doi.org/10.1002/clc.23895

Ejemplares similares

Rationale and design of the precise percutaneous coronary intervention plan (P3) study: Prospective evaluation of a virtual computed tomography‐based percutaneous intervention planner
por: Nagumo, Sakura, et al.
Publicado: (2021)

Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesions
por: Gaur, Sara, et al.
Publicado: (2016)

Coronary CT angiography derived FFR in patients with left main disease
por: Riedl, Katharina A., et al.
Publicado: (2021)

Coronary Computed Tomography Angiography Derived Fractional Flow Reserve and Plaque Stress
por: Nørgaard, Bjarne Linde, et al.
Publicado: (2016)

Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C
por: Reddy, K Rajender, et al.
Publicado: (2012)

Fractional flow reserve versus angiography in guiding management to optimize outcomes in non–ST-elevation myocardial infarction (FAMOUS-NSTEMI): Rationale and design of a randomized controlled clinical trial()
por: Berry, Colin, et al.
Publicado: (2013)

Rationale and design of the EMPYREAN study
por: Motoki, Hirohiko, et al.
Publicado: (2020)

Rationale and design of the CardioMEMS Post‐Market Multinational Clinical Study: COAST
por: Cowie, Martin R., et al.
Publicado: (2020)

Rationale and design of the AUGUST‐AHF Study
por: Zhang, Jingjing, et al.
Publicado: (2020)

German Cardiac Arrest Registry: rationale and design of G-CAR
por: Pöss, Janine, et al.
Publicado: (2022)

Computed tomography derived fractional flow reserve testing in stable patients with typical angina pectoris: influence on downstream rate of invasive coronary angiography
por: Jensen, Jesper Møller, et al.
Publicado: (2018)

Mechanisms of Diuretic Resistance Study: design and rationale
por: Cox, Zachary L., et al.
Publicado: (2020)

Rationale and design of the EPCHF trial: the early palliative care in heart failure trial (EPCHF)
por: Becher, Marc Ulrich, et al.
Publicado: (2021)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
por: Wachter, Rolf, et al.
Publicado: (2020)

Rationale and Design of the PRegnancy and Infant DEvelopment (PRIDE) Study
por: van Gelder, Marleen M H J, et al.
Publicado: (2013)

The genomics of heart failure: design and rationale of the HERMES consortium
por: Lumbers, R. Thomas, et al.
Publicado: (2021)

Kyoto Congestive Heart Failure (KCHF) study: rationale and design
por: Yamamoto, Erika, et al.
Publicado: (2017)

Rate or Rhythm Control in CRT (RHYTHMIC): Study rationale and protocol
por: Elliott, Mark K., et al.
Publicado: (2022)

TranslatiOnal Registry for CardiomyopatHies (TORCH) – rationale and first results
por: Seyler, Claudia, et al.
Publicado: (2017)

Rationale and design of a randomised trial of trientine in patients with hypertrophic cardiomyopathy
por: Farrant, John, et al.
Publicado: (2023)

The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design
por: Lainscak, Mitja, et al.
Publicado: (2019)

Regional management of worsening heart failure: rationale and design of the CHAIN‐HF registry
por: Shakoor, Abdul, et al.
Publicado: (2023)

Sacubitril/valsartan for cardioprotection in breast cancer (MAINSTREAM): design and rationale of the randomized trial
por: Tajstra, Mateusz, et al.
Publicado: (2023)

Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non‐treatable Cardiac diseasE (SCIENCE)
por: Paitazoglou, Christina, et al.
Publicado: (2019)

Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)–Coalition IV trial()()
por: Lopes, Renato D., et al.
Publicado: (2021)

Inferior vena cava ultrasound in acute decompensated heart failure: design rationale of the CAVA‐ADHF‐DZHK10 trial
por: Jobs, Alexander, et al.
Publicado: (2020)

Heart Team risk assessment with angiography‐derived fractional flow reserve determining the optimal revascularization strategy in patients with multivessel disease: Trial design and rationale for the DECISION QFR randomized trial
por: Miyata, Kotaro, et al.
Publicado: (2022)

Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease
por: Sorbets, Emmanuel, et al.
Publicado: (2017)

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study
por: Dauw, Jeroen, et al.
Publicado: (2021)

Impact of the Pandemic on NonInfected Cardiometabolic Patients: A Survey in Countries of Latin America—Rationale and Design of the CorCOVID LATAM Study
por: Lopez Santi, Ricardo, et al.
Publicado: (2020)

Rationale and study design of intravenous loop diuretic administration in acute heart failure: DIUR‐AHF
por: Palazzuoli, Alberto, et al.
Publicado: (2017)

Rationale and design of the EU‐CERT‐ICD prospective study: comparative effectiveness of prophylactic ICD implantation
por: Zabel, Markus, et al.
Publicado: (2018)

Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial
por: Morrow, Andrew J, et al.
Publicado: (2020)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure
por: Krzesiński, Paweł, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9sp0b8fi56iqeev9j0vp52b26j